Filing Details
- Accession Number:
- 0000313143-13-000191
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2013-11-04 13:22:04
- Reporting Period:
- 2013-11-01
- Filing Date:
- 2013-11-04
- Accepted Time:
- 2013-11-04 13:22:04
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
313143 | Haemonetics Corp | HAE | Surgical & Medical Instruments & Apparatus (3841) | 042882273 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1261784 | Brian Concannon | 400 Wood Road Braintree MA 02184 | President & Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2013-11-01 | 4,600 | $25.54 | 134,907 | No | 4 | M | Direct | |
Common Stock | Disposition | 2013-11-01 | 4,600 | $39.96 | 130,307 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2013-11-01 | 3,000 | $13.05 | 133,307 | No | 4 | M | Direct | |
Common Stock | Disposition | 2013-11-01 | 3,000 | $39.96 | 130,307 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Non-Qualified Stock Option (right to buy) | Disposition | 2013-11-01 | 3,000 | $39.96 | 3,000 | $13.05 |
Common Stock | Non-Qualified Stock Option (right to buy) | Disposition | 2013-11-01 | 4,600 | $39.96 | 4,600 | $25.54 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
9,000 | 2005-05-05 | 2014-05-05 | No | 4 | M | Direct |
41,180 | 2008-10-24 | 2014-10-24 | No | 4 | M | Direct |
Reported Derivative Holdings
Sec. Name | Sec. Type | Price | Date | Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
---|---|---|---|---|---|---|---|
Common Stock | Non-Qualified Stock Option (right to buy) | $26.47 | 2010-10-27 | 2016-10-27 | 159,350 | 159,350 | Direct |
Common Stock | Non-Qualified Stock Option (right to buy) | $27.28 | 2009-10-22 | 2015-10-22 | 57,176 | 57,176 | Direct |
Common Stock | Non-Qualified Stock Option (right to buy) | $27.50 | 2011-10-27 | 2017-10-27 | 236,750 | 236,750 | Direct |
Common Stock | Non-Qualified Stock Option (right to buy) | $27.69 | 2010-04-02 | 2016-04-02 | 65,690 | 65,690 | Direct |
Common Stock | Non-Qualified Stock Option (right to buy) | $30.67 | 2012-10-25 | 2018-10-25 | 219,572 | 219,572 | Direct |
Common Stock | Non-Qualified Stock Option (right to buy) | $39.06 | 2013-10-24 | 2019-10-24 | 250,382 | 250,382 | Direct |
Common Stock | Non-Qualified Stock Option (right to buy) | $41.66 | 2014-10-23 | 2019-10-23 | 234,899 | 234,899 | Direct |
Common Stock | Performance Shares | $0.00 | 2017-03-31 | 2017-12-31 | 50,000 | 50,000 | Direct |
Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
---|---|---|---|
2016-10-27 | 159,350 | 159,350 | Direct |
2015-10-22 | 57,176 | 57,176 | Direct |
2017-10-27 | 236,750 | 236,750 | Direct |
2016-04-02 | 65,690 | 65,690 | Direct |
2018-10-25 | 219,572 | 219,572 | Direct |
2019-10-24 | 250,382 | 250,382 | Direct |
2019-10-23 | 234,899 | 234,899 | Direct |
2017-12-31 | 50,000 | 50,000 | Direct |
Footnotes
- Pursuant to a 10b5-1 Plan.
- Grant to reporting person of right to buy shares of common stock exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant.
- Market Share Units represent a right to receive one share of Haemonetics Corporation common stock for each Market Stock Unit based on Haemonetics stock price during the 30 trading days prior to March 31, 2017. The number of Market Stock Units (and therefore the number of shares payable) will depend on the Companys stock price during such period. The Market Stock Units disclosed in column 5 represent a target amount. The number of shares ultimately issued could range from none to three times the target amount in column 5. The Market Stock Units were granted under the 2005 Haemonetics Corporation Long-Term Incentive Compensation Plan and are exempt under Rule 16b-3(d).